Aug 12, 2020
Moleculin Biotech, Inc. Reports Financial Results for the Quarter Ended June 30, 2020
Jun 04, 2020
Moleculin Announces Submission to Expand Clinical Sites in European AML Trial
Jun 02, 2020
Moleculin Announces Emory University Clinical Trial of WP1066 Begins Enrollment
May 27, 2020
Moleculin Announces Common Stock Will Resume Trading on the NASDAQ on May 28, 2020
May 27, 2020
Moleculin Provides Update on Coronavirus Drug Development
May 18, 2020
Moleculin Announces Nasdaq Trading Halt Pending Receipt of Additional Information
May 11, 2020
Moleculin Provides Additional Comments Regarding Trading Halt
May 08, 2020
Moleculin Announces Intention to Adjourn 2020 Annual Meeting of Stockholders to June 15, 2020
May 04, 2020
Moleculin Announces Trading Halt
Apr 29, 2020
Moleculin to Speak on COVID-19 Panel at Maxim Group's Infectious Disease Virtual Conference
Apr 28, 2020
Moleculin Approved to Accelerate European Clinical Trial
Apr 22, 2020
Moleculin Announces Head of NIAID Antiviral Drug Discovery and Development Center Joins COVID-19 Drug Development Team
Apr 20, 2020
Moleculin Announces Agreement with ImQuest Biosciences to Expand Coronavirus Testing
Apr 16, 2020
Moleculin to Host Investor Conference Call to Discuss COVID-19 Potential for Drug Candidate Today
Apr 14, 2020
Moleculin Announces Investor Conference Call to Discuss COVID-19 Potential for Drug Candidate
Apr 08, 2020
Moleculin Announces Active Compound in WP1122 Reduces Coronavirus Replication In Vitro by 100%
Mar 19, 2020
Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 2019
Mar 17, 2020
Moleculin Signs Agreement with UTMB to Test WP1122 on a Range of Viruses, Including Coronavirus
Mar 10, 2020
Moleculin Announces Dr. Hongbo Zhai Joins Science Advisory Board
Feb 20, 2020
Moleculin Announces Positive Independent Report of No Cardiotoxicity in Annamycin Phase 1 To Date